Reig Jofre, member of CataloniaBio & HealthTech, has achieved significant success together with their partner Maruishi Pharmaceutical in Japan. They have produced in Barcelona and marketed in Japan 15 million vials of Remifentanil, a state-of-the-art intravenous anesthetic for hospital use. This product, internally developed by the company, is manufactured at Reig Jofre's sterile injectables and lyophilized plant. 

Ysios Capital, a member of CataloniaBio & HealthTech, has announced its participation in the financing round of the company Kynexis (Naarden, Netherlands) for a total amount of 57 million euros. The company, co-founded by Ysios Capital and Forbion, has an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and market the product KYN5356 worldwide.

Oryzon Genomics, member of CataloniaBio & HealthTech, has announced that it is developing a new molecule for the treatment of personality disorders. This new molecule, called ORY-304, acts as a selective inhibitor of LSD1, an enzyme involved in the epigenetic regulation of genes related to behaviour and emotions. Personality disorders are a group of mental disorders that affect how people perceive, think, and relate to others. These disorders are difficult to treat and have a significant impact on the quality of life of those affected. 

Gate2Brain, member of CataloniaBio & HealthTech, has announced that it has received funding from EIT Health, a European health innovation network. This investment will allow Gate2Brain to advance the development of its revolutionary technology for drug administration to the brain. 

Sant Joan de Deu Hospital, member of CataloniaBio & HealthTech, and Microsoft have announced a strategic collaboration for the creation of an Artificial Intelligence (AI) laboratory aimed at developing digital health projects. This initiative aims to promote innovation in the field of health through the application of advanced technologies. 

Peptomyc, member of CataloniaBio & HealthTech, announced today that it has received a €5 million grant from the EIC (European Innovation Council) acceleration program of Horizon Europe. This funding will allow Peptomyc to carry out a phase 1b clinical trial with its drug candidate OMO-103 in patients, as well as scale up its manufacturing process. 

At the Germans Trias i Pujol Research Institute (IGTP), member of CataloniaBio & HealthTech, the day "Translational research and innovation through EATRIS" was held. The purpose of this event was to discuss the progress and perspectives of EATRIS both in Spain and in Europe, and to highlight the research and innovation activity of the IGTP. 

Anaxomics, member of CataloniaBio & HealthTech, is at the forefront of an innovative project aimed at analysing the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Under the name Project Mathrix, this study, in collaboration with Takeda and a multidisciplinary team of experts, uses virtual patient simulations and Artificial Intelligence techniques to deepen the understanding of ADHD treatments. 

The biotechnology company GoodGut, a member of CataloniaBio & HealthTech, in collaboration with the Galician Department of Health, has initiated a pilot study of an innovative test based on quantitative PCR techniques. This test is intended to assess its potential integration into the Galician Colorectal Cancer Screening Programme. Previous studies have shown that GoodGut's test, by identifying a specific bacterial signature of colorectal cancer, can enhance the efficiency of disease diagnosis. 

Newborn Solutions, the medical devices startup member of CataloniaBio & HealthTech, announces that it has changed its brand. Its new name and identity: Kriba. The rebranding of the company represents a significant milestone in their journey, marking their commitment to innovation, health impact, and global accessibility in the field of non-invasive screening, detection, and monitoring of infections in serous fluids. “Months of planning, collaboration, and creative efforts have culminated in the birth of Kriba”, explain the company.

Wivi Vision, member of CataloniaBio & HealthTech, along with Bandora emerged as winners in the inaugural ‘pitch’ of the HearstLab 2023 initiative, which aims to promote female talent and women-led companies. 

Moreover, it is a field that is still full of uncertainties and, for this reason, CataloniaBio & HealthTech has brought together four experts from very different fields, such as business, health care providers, teaching and public agencies, to give their point of view and share their impressions, experiences and best practices in this area. The session was moderated by Alfons Nonell, CEO of DevsHealth and chair of the CataloniaBio & HealthTech Internal Digital Committee, who proposed the theme of the session.

Vitala, member of CataloniaBio & HealthTech, is one of the three Catalan startups to be among the first to access ACCIÓ Startup Capital co-investment line for 'deeptech' startups, launched in 2023 with a total budget of 2.5 million euros. 

MiMARK Diagnostics, member of CataloniaBio & HealthTech, has successfully raised a total of 1.2 million euros for an innovative project focused on the diagnosis of endometrial cancer. 

CataloniaBio & HealthTech was a special guest at the second edition of the Foro BIO 2023, held this 11 October in Cordoba, Argentina. Javier Selva, CEO of CataloniaBio & HealthTech, participated with a conference focused on competitiveness policies, to explain the health ecosystem in Catalonia and the strengths of the 30 years of cluster policy in Catalonia.

SpliceBio, una empresa de teràpia gènica que utilitza l’splicing de proteïnes per desenvolupar la propera generació de teràpies genètiques, ha anunciat la signatura d’un acord exclusiu de col·laboració i llicència amb Spark Therapeutics per utilitzar la plataforma d’splicing de proteïnes propietat d’SpliceBio amb la finalitat de desenvolupar una teràpia gènica per una malaltia hereditària de la retina no revelada. SpliceBio és membre de CataloniaBio & HealthTech.

Oncoheroes Biosciences, membre de CataloniaBio & HealthTech, ha anunciat que l'Administració d'Aliments i Medicaments (FDA) dels Estats Units ha concedit la designació de medicament orfe al dovitinib pel seu ús en el tractament de l'osteosarcoma.

Una vintena de CEOs de CataloniaBio &HealthTech es van reunir el dimarts 10 d’octubre, al HUB cambraDigital (Cambra de Comerç de Barcelona), en la darrera edició del CEO Council. El convidat especial en aquesta edició ha estat Xavier Prats, actualment president del Patronat de l’Hospital de Sant Pau (Barcelona); la benvinguda i moderació de la conversa ha estat a càrrec de Joan Puig de Dou, CEO de Kymos i President de CataloniaBio & HealthTech.

Almirall, a global biopharmaceutical company focused on medical dermatology, today announced an agreement with Centrient Pharmaceuticals, a global business-to-business pioneer in sustainable, biosynthetic pharmaceutical products, including antibiotics, next-generation statins, and anti-fungals,, to open its new dedicated innovation lab at Almirall’s R&D centre. Centrient's new Innovation Laboratory will start operations in the first quarter of 2024.

Agomab Therapeutics NV today announced the closing of a $100 million Series C financing round led by Fidelity Management & Research Company (FMR), with participation from new investors EQT Life Sciences (EQT), Canaan, Kohlberg Kravis Roberts & Co (KKR Dawn) and existing investors Asabys , member of CataloniaBio & HealthTech, (through its funds Sabadell Asabys and Top Up Fund), Pfizer, Pontifax, Redmile, Cormorant, Andera Partners, AdBio and Walleye.